H.C. Wainwright downgrades RAPT shares to neutral after clinical trial halt By Investing.com
[ad_1] © Reuters. On Wednesday, RAPT Therapeutics (NASDAQ:) faced a downgrade from H.C. Wainwright, moving from Buy to Neutral, following a pause in all clinical...
CG Oncology stock initiated with buy rating and $75 target by H.C. Wainwright By Investing.com
[ad_1] © Reuters. On Wednesday, H.C. Wainwright initiated coverage on CG Oncology (NASDAQ:CGON), issuing a Buy rating and setting a price target of $75.00. The...